Pharmaceutical

Citius aims to bounce back from Lymphir setback

Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.

Mar 7, 2024 - 18:00
Citius aims to bounce back from Lymphir setback
Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.
Read the original article

Tags:

Previous Article

CTS Europe: The roadmap for generative AI in the pharma industry

Next Article

Sionna raises $182m to double down in cystic fibrosis drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: More hospital pharmacists are rationing drugs due to increasing shortages

STAT+: More hospital pharmacists are rationing drugs du...

Aug 11, 2023

STAT+: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions

STAT+: Novartis is scolded by U.K. trade group for the ...

Sep 20, 2023

Galecto downsizes by 70% following Phase II trial failure

Galecto downsizes by 70% following Phase II trial failure

Sep 27, 2023